DCTH Delcath Systems Inc: רווח למניה לשנה מתגלגלת

This daily price chart illustrates that the current market quotes for Delcath Systems, Inc. (DCTH) EPS (TTM) stand at 712.60, complementing data on the implementation of ESG environmental standards within the production of chemotherapy systems. Delcath Systems, Inc. (DCTH) minimizes systemic toxicity by developing blood purification filters for liver tumor therapy. The business's competitive advantage is based on Hepzato Kit patents and the complexity of training specialists to operate this platform.

This indicator measures the dynamics of net earnings per share over the last twelve months relative to the same period last year. By analyzing the relative change in EPS YoY (TTM) on the GURU.Markets platform, an investor assesses the commercialization efficiency of the unique chemoperfusion system from Delcath Systems, Inc. (DCTH). The absence of direct competitors in the treatment of liver metastases should convert into steady growth of this metric. A stable upward trend will confirm the fundamental resilience of the business within the oncology sector.